When and How Disease-Modifying Drugs for Multiple Sclerosis Should Be Changed in Daily Practice

Clinical and Experimental Neuroimmunology - United Kingdom
doi 10.1111/cen3.12380
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley


Related search